Parallax Volatility Advisers
VRTX icon

Parallax Volatility Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Parallax Volatility Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$40.3K – 2183
2024
Q4 		$40.3K Buy
+100
New +$46.4K ﹤0.01% 1801
2024
Q2 		– Sell
-24,600
Closed -$10.3M – 2284
2024
Q1 		$10.3M Buy
24,600
+5,000
+26% +$2.11M 0.02% 500
2023
Q4 		$7.98M Buy
19,600
+5,100
+35% +$1.88M 0.02% 654
2023
Q3 		$5.04M Buy
14,500
+12,200
+530% +$4.27M 0.01% 760
2023
Q2 		$809K Sell
2,300
-500
-18% -$168K ﹤0.01% 1489
2023
Q1 		$882K Sell
2,800
-5,800
-67% -$1.74M ﹤0.01% 1551
2022
Q4 		$2.48M Sell
8,600
-2,200
-20% -$670K ﹤0.01% 1324
2022
Q3 		$3.13M Buy
10,800
+1,600
+17% +$460K ﹤0.01% 1210
2022
Q2 		$2.59M Sell
9,200
-61,800
-87% -$16.5M ﹤0.01% 1243
2022
Q1 		$18.5M Buy
71,000
+42,700
+151% +$10.1M 0.01% 535
2021
Q4 		$6.21M Buy
28,300
+7,800
+38% +$1.52M 0.01% 1096
2021
Q3 		$3.72M Sell
20,500
-12,100
-37% -$2.36M ﹤0.01% 1366
2021
Q2 		$6.57M Buy
32,600
+10,600
+48% +$2.22M 0.01% 1080
2021
Q1 		$4.73M Buy
22,000
+13,700
+165% +$3.01M ﹤0.01% 1312
2020
Q4 		$1.96M Buy
8,300
+6,600
+388% +$1.51M ﹤0.01% 1898
2020
Q3 		$461K Buy
1,700
+500
+42% +$138K ﹤0.01% 2274
2020
Q2 		$348K Sell
1,200
-1,900
-61% -$515K ﹤0.01% 2088
2020
Q1 		$739K Sell
3,100
-19,000
-86% -$4.36M ﹤0.01% 1585
2019
Q4 		$4.84M Buy
22,100
+6,300
+40% +$1.28M 0.01% 921
2019
Q3 		$2.68M Buy
15,800
+12,600
+394% +$2.23M ﹤0.01% 1030
2019
Q2 		$588K Buy
3,200
+2,800
+700% +$489K ﹤0.01% 1451
2019
Q1 		$74K Sell
400
-10,200
-96% -$1.88M ﹤0.01% 2187
2018
Q4 		$1.76M Buy
10,600
+100
+1% +$17.3K ﹤0.01% 1103
2018
Q3 		$2.02M Buy
10,500
+500
+5% +$89K ﹤0.01% 1019
2018
Q2 		$1.7M Buy
+10,000
New +$1.55M ﹤0.01% 956
2017
Q2 		– Sell
-30,000
Closed -$3.28M – 4119
2017
Q1 		$3.28M Buy
+30,000
New +$2.64M 0.01% 702
2015
Q4 		– Sell
-15,000
Closed -$1.56M – 4013
2015
Q3 		$1.56M Buy
+15,000
New +$1.93M ﹤0.01% 1125

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Parallax Volatility Advisers's VRTX Position: Q2 2026 in Review

Parallax Volatility Advisers opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 599 shares worth $298K. The stake represents ﹤0.01% of the portfolio and ranks #1190 among its holdings. This is a return to the name: Parallax Volatility Advisers previously reported a position in VRTX as recently as Q2 2025.

Parallax Volatility Advisers first reported a position in VRTX in Q2 2014 and has held it in 30 quarters since. The position peaked at $8.99M in Q1 2017. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Parallax Volatility Advisers held 599 shares of Vertex Pharmaceuticals worth $298K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Parallax Volatility Advisers position in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q2 2026, its #1190 holding.
  • Parallax Volatility Advisers first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 30 quarters since.
  • Parallax Volatility Advisers's Vertex Pharmaceuticals position peaked at $8.99M in Q1 2017.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Parallax Volatility Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.